Galasko C S, Courtney P, Jayne M, Coxhead P F, Russell S
Department of Orthopaedic Surgery, University of Manchester, Hope Hospital, Salford, England.
Curr Med Res Opin. 1988;10(10):656-62. doi: 10.1185/03007998809111115.
A single-blind, parallel study was carried out in 54 patients with post-operative pain after minor orthopaedic procedures to compare the efficacy and tolerance of naproxen sodium and dihydrocodeine tartrate. Patients were allocated at random to receive oral treatment as soon as analgesia became necessary with an initial dose of either 550 mg naproxen sodium or 30 mg dihydrocodeine tartrate, then doses of 275 mg and 30 mg, respectively, when required up to a maximum of 5 doses per day for 3 days. Assessments were made of pain severity and pain relief 2 and 4 hours after the first dose and at the end of each day. The results indicated that naproxen sodium gave statistically significantly greater pain relief than dihydrocodeine tartrate after the first dose. Both treatments were well tolerated and few side-effects were reported. Three patients in each group were withdrawn due to lack of efficacy (combined with adverse effects in 1 naproxen sodium patient), and 1 patient in each group was withdrawn because of side-effects.
一项单盲平行研究对54例接受小型骨科手术后有疼痛的患者进行，以比较萘普生钠和酒石酸二氢可待因的疗效和耐受性。一旦需要镇痛，患者被随机分配接受口服治疗，初始剂量为550毫克萘普生钠或30毫克酒石酸二氢可待因，然后根据需要分别给予275毫克和30毫克剂量，每天最多5剂，共3天。在首剂后2小时和4小时以及每天结束时评估疼痛严重程度和疼痛缓解情况。结果表明，首剂后萘普生钠在统计学上比酒石酸二氢可待因能更显著地减轻疼痛。两种治疗耐受性良好，报告的副作用较少。每组有3例患者因缺乏疗效而退出（1例萘普生钠患者伴有不良反应），每组有1例患者因副作用退出。
